Filing Flows › Citius Oncology (CTOR) › R&D spending
Citius Oncology (CTOR) R&D spending by quarter
Citius Oncology's R&D spending was $218K in Q3 FY26 (third quarter fiscal 2026), -80% from Q2 FY26. Over the last 3 quarters it ranged from $218K (Q3 FY26) to $1.1M (Q2 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $218K | -80% | — |
| Q2 FY26 | $1.1M | +6% | — |
| Q1 FY26 | $1.0M | — | — |
Q3 FY26 at a glance
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Citius Oncology's R&D spending?
Citius Oncology's R&D spending was $218K in Q3 FY26 (third quarter fiscal 2026), -80% from Q2 FY26.
How has Citius Oncology's R&D spending changed?
Over the last 3 quarters it ranged from $218K (Q3 FY26) to $1.1M (Q2 FY26).